Graphene oxide (GO) provides a versatile platform for the development of antimicrobial and anti-adhesive materials, particularly when combined with covalently immobilized bioactive compounds but translating antibiotic activity into a stable layer without clinically relevant drug leaching remains challenging. Here, we report a covalently engineered GO-moxifloxacin (GO-MOX) composite obtained by grafting MOX onto ethylenediamine-functionalized GO via carbodiimide coupling. The successful functionalization was supported by complementary physicochemical analyses, including FTIR, NMR, Raman, XPS, TGA, SEM/EDS and XRD. TGA indicated a high MOX loading of approximately 44.75 wt%, while HPLC analysis revealed that extractable/free MOX represented only 0.0586% of the total MOX content, supporting the predominantly covalent and minimally releasing character of the material. GO-MOX showed pronounced antimicrobial activity against representative ESKAPEE pathogens, with MIC values of 7.81 μg/mL against E. coli and 62.5 μg/mL against the tested Gram-positive strains. In the antimycobacterial assay, GO-MOX markedly inhibited the growth of both drug-susceptible and rifampicin/isoniazid-resistant Mycobacterium tuberculosis strains under the tested conditions. Anti-adherence activity was observed at sub-inhibitory concentrations, with MBEC values of 1.95 μg/mL for E. coli and 7.81 μg/mL for S. aureus, suggesting interference with early bacterial attachment. Additional analyses on mature biofilms formed on titanium substrates showed that GO-based treatments, particularly GO-MOX, affected biofilm viability, promoted membrane permeabilization, and altered extracellular matrix components, including extracellular proteins, nucleic acids/eDNA-like fractions and polysaccharides. In vitro cellular assays showed that normal MRC-5 fibroblasts recovered metabolic activity to ≥80% after 72 h, whereas A549 cells displayed a concentration- and time-dependent decrease in viability. ROS generation and Caspase-3 activity further suggested that the selective antiproliferative response observed in A549 cells may be associated, at least in part, with oxidative stress-mediated apoptotic mechanisms. In silico target prediction and structural inspection of MOX-topoisomerase complexes suggested that GO-MOX may retain a MOX-related contribution involving bacterial DNA gyrase/topoisomerase IV, while GO may provide additional contact-associated interfacial effects. Overall, GO-MOX emerges as a promising antimicrobial and anti-adhesive nanoplatform with cell-selective antiproliferative effects, supporting its further investigation for the future development of biomedical antimicrobial surfaces and coatings.
No takes yet. Share an insight, caveat, or question.
Marinaş et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: